205996-41-4

Basic information

• Product Name: (3RS)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one
• Synonyms: (3RS)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one
• CAS NO: 205996-41-4
• Molecular Weight: 341.453
• Mol File: 205996-41-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (3RS)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3RS)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one(205996-41-4)
• EPA Substance Registry System: (3RS)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one(205996-41-4)

Safety Data

• Hazardous Substances Data: 205996-41-4(Hazardous Substances Data)

Upstream product

• 205996-05-0 (3RS)-3-benzyloxycarbonylamino-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one 
• 62819-85-6 2-amino-3-methyl-propiophenone 
• 95-53-4 o-toluidine 
• 205996-36-7 (3RS)-3-benzyloxycarbonylamino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one 

Downstream Products

• 205998-80-7 (3S)-1-cyclohexylcarbonylmethyl-3-[(S)-phenylalanyl]amino-5-ethyl-2,3-dihydro-9-methyl-1H-1,4-benzodiazepin-2-one 
• 205998-79-4 (3R)-1-cyclohexylcarbonylmethyl-3-[(S)-phenylalanyl]amino-5-ethyl-2,3-dihydro-9-methyl-1H-1,4-benzodiazepin-2-one 
• 205998-81-8 (3S)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one 
• 205998-89-6 (3R)-3-amino-1-cyclohexyl-carbonylmethyl-2,3-dihydro-5-ethyl-9-methyl-1H-1,4-benzodiazepin-2-one 
• 205998-78-3 (3RS)-1-cyclohexylcarbonylmethyl-3-[N-tert-butoxycarbonyl-(S)-phenylalanyl]amino-5-ethyl-2,3-dihydro-9-methyl-1H-1,4-benzodiazepin-2-one 

Relevant articles and documents

Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419

In our continuing research for dual CCK-A and -B antagonists, according to our hypothesis that dual CCKA and -B antagonists should be more efficacious than selective CCK-A antagonists for the treatment of pancreatitis, we have prepared various 5-alkyl-9-m